- Home
- CHRS vs AKA Comparison
CHRS vs AKA Comparison
Compare CHRS & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- AKA
- Stock Information
- Founded
- CHRS 2010
- AKA 2018
- Country
- CHRS United States
- AKA United States
- Employees
- CHRS N/A
- AKA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- AKA Catalog/Specialty Distribution
- Sector
- CHRS Health Care
- AKA Consumer Discretionary
- Exchange
- CHRS Nasdaq
- AKA Nasdaq
- Market Cap
- CHRS 112.5M
- AKA 126.7M
- IPO Year
- CHRS 2014
- AKA 2021
- Fundamental
- Price
- CHRS $0.76
- AKA $12.00
- Analyst Decision
- CHRS Buy
- AKA Buy
- Analyst Count
- CHRS 3
- AKA 4
- Target Price
- CHRS $4.68
- AKA $22.50
- AVG Volume (30 Days)
- CHRS 1.2M
- AKA 8.3K
- Earning Date
- CHRS 08-07-2025
- AKA 08-06-2025
- Dividend Yield
- CHRS N/A
- AKA N/A
- EPS Growth
- CHRS N/A
- AKA N/A
- EPS
- CHRS N/A
- AKA N/A
- Revenue
- CHRS $272,251,000.00
- AKA $586,514,000.00
- Revenue This Year
- CHRS N/A
- AKA $6.60
- Revenue Next Year
- CHRS $132.69
- AKA $4.14
- P/E Ratio
- CHRS $1.79
- AKA N/A
- Revenue Growth
- CHRS 19.87
- AKA 8.09
- 52 Week Low
- CHRS $0.66
- AKA $7.00
- 52 Week High
- CHRS $2.43
- AKA $32.25
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- AKA 48.28
- Support Level
- CHRS $0.74
- AKA $12.32
- Resistance Level
- CHRS $0.90
- AKA $12.91
- Average True Range (ATR)
- CHRS 0.05
- AKA 0.55
- MACD
- CHRS 0.01
- AKA -0.15
- Stochastic Oscillator
- CHRS 13.56
- AKA 36.97
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.